{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:48:18Z","timestamp":1783547298142,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00213-020-05716-4","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T02:03:45Z","timestamp":1609985025000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review"],"prefix":"10.1007","volume":"238","author":[{"given":"Beatriz Oda","family":"Plasencia-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Rodr\u00edguez-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Rico-Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rubio-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Torell\u00f3-Iserte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-7132","authenticated-orcid":false,"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"2","key":"5716_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1331\/154434504773062582","volume":"44","author":"J Abarca","year":"2004","unstructured":"Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB (2004) Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 44(2):136\u2013141. https:\/\/doi.org\/10.1331\/154434504773062582","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"5716_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0269881116684337","volume":"31","author":"T Acciavatti","year":"2017","unstructured":"Acciavatti T, Martinotti G, Corbo M, Cinosi E, Lupi M, Ricci F, Di Scala R, D\u2019Ugo E, De Francesco V, De Caterina R, di Giannantonio M (2017) Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol 31(4):453\u2013460. https:\/\/doi.org\/10.1177\/0269881116684337","journal-title":"J Psychopharmacol"},{"issue":"9","key":"5716_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35(9):1687\u20131693. https:\/\/doi.org\/10.1124\/dmd.107.015511","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"5716_CR4","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1345\/aph.1P139","volume":"44","author":"GL Aung","year":"2010","unstructured":"Aung GL, O\u2019Brien JG, Tien PG, Kawamoto LS (2010) Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 44(11):1850\u20131854. https:\/\/doi.org\/10.1345\/aph.1P139","journal-title":"Ann Pharmacother"},{"issue":"4","key":"5716_CR5","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mour\u00e3o MPG, Brito-Sousa JD, Ba\u00eda-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A et al (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: a randomized clinical trial. JAMA Netw Open 3(4):e208857. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8857","journal-title":"JAMA Netw Open"},{"key":"5716_CR6","doi-asserted-by":"publisher","unstructured":"Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D (2020) Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.017","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"5716_CR7","doi-asserted-by":"publisher","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2001282","DOI":"10.1056\/NEJMoa2001282"},{"issue":"2","key":"5716_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00128071-200506020-00005","volume":"6","author":"SD Chao","year":"2005","unstructured":"Chao SD, Maibach HI (2005) Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 6(2):105\u2013111. https:\/\/doi.org\/10.2165\/00128071-200506020-00005","journal-title":"Am J Clin Dermatol"},{"key":"5716_CR9","doi-asserted-by":"publisher","unstructured":"Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents:105932. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105932","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"issue":"1","key":"5716_CR10","first-page":"77","volume":"40","author":"RR Conley","year":"2007","unstructured":"Conley RR, Kelly DL (2007) Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 40(1):77\u201397","journal-title":"Psychopharmacol Bull"},{"issue":"12","key":"5716_CR11","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s00134-001-1132-2","volume":"27","author":"E Ely","year":"2001","unstructured":"Ely E, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard G, Inouye S (2001) The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med 27(12):1892\u20131900. https:\/\/doi.org\/10.1007\/s00134-001-1132-2","journal-title":"Intensive Care Med"},{"issue":"14","key":"5716_CR12","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1001\/jama.291.14.1753","volume":"291","author":"EW Ely","year":"2004","unstructured":"Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Inouye SK, Bernard GR, Dittus RS (2004) Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 291(14):1753\u20131762. https:\/\/doi.org\/10.1001\/jama.291.14.1753","journal-title":"JAMA"},{"issue":"2","key":"5716_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.104.075416","volume":"312","author":"CS Ernest","year":"2005","unstructured":"Ernest CS, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312(2):583\u2013591. https:\/\/doi.org\/10.1124\/jpet.104.075416","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"5716_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1574884713666180223123947","volume":"12","author":"CV Etchegoyen","year":"2017","unstructured":"Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G (2017) Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol 12(4):210\u2013222. https:\/\/doi.org\/10.2174\/1574884713666180223123947","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"5716_CR15","doi-asserted-by":"publisher","first-page":"e209035","DOI":"10.1001\/jamanetworkopen.2020.9035","volume":"3","author":"SD Fihn","year":"2020","unstructured":"Fihn SD, Perencevich E, Bradley SM (2020) Caution needed on the use of chloroquine and hydroxychloroquine for coronavirus disease 2019. JAMA Netw Open 3(4):e209035\u2013e209035. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.9035","journal-title":"JAMA Netw Open"},{"issue":"7","key":"5716_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","volume":"42","author":"MM Foisy","year":"2008","unstructured":"Foisy MM, Yakiwchuk EM, Hughes CA (2008) Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 42(7):1048\u20131059. https:\/\/doi.org\/10.1345\/aph.1K615","journal-title":"Ann Pharmacother"},{"issue":"61","key":"5716_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0011-393X(00)80036-3","volume":"8","author":"TR Fulda","year":"2000","unstructured":"Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ, Acknowledgments, U. P. D. U. R. A. P. of the U. P. D. U. R. A. P. are listed in the (2000) Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res 8(61):540\u2013548","journal-title":"Curr Ther Res"},{"issue":"1","key":"5716_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JCP.0b013e3182a6096e","volume":"34","author":"P Gareri","year":"2014","unstructured":"Gareri P, De Fazio P, Manfredi VGL, De Sarro G (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34(1):109\u2013123. https:\/\/doi.org\/10.1097\/JCP.0b013e3182a6096e","journal-title":"J Clin Psychopharmacol"},{"key":"5716_CR19","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honor\u00e9 S, Colson P, Chabri\u00e8re E, La Scola B, Rolain J-M, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"issue":"2","key":"5716_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12245-010-0175-y","volume":"3","author":"MJ Geraci","year":"2010","unstructured":"Geraci MJ, McCoy SL, Crum PM, Patel RA (2010) Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med 3(2):81\u201384. https:\/\/doi.org\/10.1007\/s12245-010-0175-y","journal-title":"Int J Emerg Med"},{"key":"5716_CR21","doi-asserted-by":"publisher","unstructured":"Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ (2020) Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc 0(0). https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.024","DOI":"10.1016\/j.mayocp.2020.03.024"},{"issue":"10","key":"5716_CR22","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","volume":"116","author":"TJ Guzik","year":"2020","unstructured":"Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D\u2019Acquisto F, Nicklin SA, Marian AJ, Nosalski R, Murray EC, Guzik B, Berry C, Touyz RM, Kreutz R, Wang DW et al (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 116(10):1666\u20131687. https:\/\/doi.org\/10.1093\/cvr\/cvaa106","journal-title":"Cardiovasc Res"},{"issue":"1","key":"5716_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-018-1188-2","volume":"16","author":"IL Haeusler","year":"2018","unstructured":"Haeusler IL, Chan XHS, Gu\u00e9rin PJ, White NJ (2018) The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 16(1):200. https:\/\/doi.org\/10.1186\/s12916-018-1188-2","journal-title":"BMC Med"},{"key":"5716_CR24","doi-asserted-by":"publisher","unstructured":"Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F (2020) Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med 0(0) null. https:\/\/doi.org\/10.1056\/NEJMc2008597","DOI":"10.1056\/NEJMc2008597"},{"issue":"4","key":"5716_CR25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan L-N (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41(4):674\u2013680. https:\/\/doi.org\/10.1345\/aph.1H423","journal-title":"Ann Pharmacother"},{"issue":"5","key":"5716_CR26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1128\/AAC.41.5.898","volume":"41","author":"A Hsu","year":"1997","unstructured":"Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41(5):898\u2013905","journal-title":"Antimicrob Agents Chemother"},{"key":"5716_CR27","doi-asserted-by":"publisher","unstructured":"Jean S-S, Lee P-I, Hsueh P-R (2020) Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect = Wei Mian Yu Gan Ran Za Zhi. https:\/\/doi.org\/10.1016\/j.jmii.2020.03.034","DOI":"10.1016\/j.jmii.2020.03.034"},{"issue":"10","key":"5716_CR28","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s00415-019-09200-8","volume":"266","author":"B Jin","year":"2019","unstructured":"Jin B, Liu H (2019) Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. J Neurol 266(10):2363\u20132375. https:\/\/doi.org\/10.1007\/s00415-019-09200-8","journal-title":"J Neurol"},{"issue":"5","key":"5716_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00002826-200209000-00004","volume":"25","author":"F Jover","year":"2002","unstructured":"Jover F, Cuadrado J-M, Andreu L, Merino J (2002) Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 25(5):251\u2013253. https:\/\/doi.org\/10.1097\/00002826-200209000-00004","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"5716_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1345\/aph.1A335","volume":"36","author":"DV Kelly","year":"2002","unstructured":"Kelly DV, B\u00e9\u00efque LC, Bowmer MI (2002) Extrapyramidal symptoms with ritonavir\/indinavir plus risperidone. Ann Pharmacother 36(5):827\u2013830. https:\/\/doi.org\/10.1345\/aph.1A335","journal-title":"Ann Pharmacother"},{"issue":"12","key":"5716_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","volume":"27","author":"WK Kennedy","year":"2013","unstructured":"Kennedy WK, Jann MW, Kutscher EC (2013) Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 27(12):1021\u20131048. https:\/\/doi.org\/10.1007\/s40263-013-0114-6","journal-title":"CNS Drugs"},{"issue":"1\u20132","key":"5716_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1081\/dmr-120001389","volume":"34","author":"RB Kim","year":"2002","unstructured":"Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34(1\u20132):47\u201354. https:\/\/doi.org\/10.1081\/dmr-120001389","journal-title":"Drug Metab Rev"},{"issue":"5","key":"5716_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","volume":"43","author":"JR King","year":"2004","unstructured":"King JR, Wynn H, Brundage R, Acosta EP (2004) Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 43(5):291\u2013310. https:\/\/doi.org\/10.2165\/00003088-200443050-00003","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"5716_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5603\/AIT.a2018.0011","volume":"50","author":"K Kotfis","year":"2018","unstructured":"Kotfis K, Marra A, Ely EW (2018) ICU delirium\u2014a diagnostic and therapeutic challenge in the intensive care unit. Anaesthesiol Intensive Ther 50(2):160\u2013167. https:\/\/doi.org\/10.5603\/AIT.a2018.0011","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"5","key":"5716_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1176\/appi.psy.41.5.453","volume":"41","author":"SI Lee","year":"2000","unstructured":"Lee SI, Klesmer J, Hirsch BE (2000) Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report. Psychosomatics 41(5):453\u2013454. https:\/\/doi.org\/10.1176\/appi.psy.41.5.453","journal-title":"Psychosomatics"},{"issue":"9896","key":"5716_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England) 382(9896):951\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet (London, England)"},{"issue":"12","key":"5716_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"AR Maher","year":"2011","unstructured":"Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12):1359\u20131369. https:\/\/doi.org\/10.1001\/jama.2011.1360","journal-title":"JAMA"},{"issue":"3","key":"5716_CR38","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/PCC.20com02677","volume":"22","author":"Z Mansuri","year":"2020","unstructured":"Mansuri Z, Adnan M, Jolly T (2020) Ritonavir\/lopinavir and its potential interactions with psychiatric medications: a COVID-19 perspective. Primary Care Companion CNS Disord 22(3):0\u20130. https:\/\/doi.org\/10.4088\/PCC.20com02677","journal-title":"Primary Care Companion CNS Disord"},{"key":"5716_CR39","doi-asserted-by":"publisher","unstructured":"Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1127","DOI":"10.1001\/jamaneurol.2020.1127"},{"issue":"7","key":"5716_CR40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/1060028015581848","volume":"49","author":"L Meemken","year":"2015","unstructured":"Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A, Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A (2015) Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy. Ann Pharmacother 49(7):796\u2013807","journal-title":"Ann Pharmacother"},{"issue":"7","key":"5716_CR41","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5716_CR42","doi-asserted-by":"publisher","unstructured":"Monteagudo LA, Boothby A, Gertner E (2020) Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11135","DOI":"10.1002\/acr2.11135"},{"key":"5716_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.psychres.2019.03.041","volume":"275","author":"S Monteith","year":"2019","unstructured":"Monteith S, Glenn T (2019) A comparison of potential psychiatric drug interactions from six drug interaction database programs. Psychiatry Res 275:366\u2013372. https:\/\/doi.org\/10.1016\/j.psychres.2019.03.041","journal-title":"Psychiatry Res"},{"key":"5716_CR44","doi-asserted-by":"publisher","first-page":"m1461","DOI":"10.1136\/bmj.m1461","volume":"369","author":"National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement","year":"2020","unstructured":"National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement (2020) Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ (Clinical Research Ed) 369:m1461. https:\/\/doi.org\/10.1136\/bmj.m1461","journal-title":"BMJ (Clinical Research Ed)"},{"key":"5716_CR45","doi-asserted-by":"publisher","unstructured":"O\u2019Hanlon S, Inouye SK (2020) Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afaa094","DOI":"10.1093\/ageing\/afaa094"},{"issue":"1","key":"5716_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"issue":"4","key":"5716_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3163\/1536-5050.104.4.007","volume":"104","author":"RI Patel","year":"2016","unstructured":"Patel RI, Beckett RD (2016) Evaluation of resources for analyzing drug interactions. J Med Lib Assoc 104(4):290\u2013295. https:\/\/doi.org\/10.3163\/1536-5050.104.4.007","journal-title":"J Med Lib Assoc"},{"issue":"4","key":"5716_CR48","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00004714-200208000-00006","volume":"22","author":"SR Penzak","year":"2002","unstructured":"Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW (2002) Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 22(4):366\u2013370. https:\/\/doi.org\/10.1097\/00004714-200208000-00006","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"5716_CR49","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1592\/phco.29.11.1386","volume":"29","author":"TM Pollack","year":"2009","unstructured":"Pollack TM, McCoy C, Stead W (2009) Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 29(11):1386\u20131391. https:\/\/doi.org\/10.1592\/phco.29.11.1386","journal-title":"Pharmacotherapy"},{"issue":"11","key":"5716_CR50","doi-asserted-by":"publisher","first-page":"e81208","DOI":"10.1371\/journal.pone.0081208","volume":"8","author":"E Raschi","year":"2013","unstructured":"Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, Bennie M, Barbui C, Wettermark B, Sturkenboom M, De Ponti F (2013) Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 8(11):e81208. https:\/\/doi.org\/10.1371\/journal.pone.0081208","journal-title":"PLoS One"},{"issue":"3","key":"5716_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360(3):225\u2013235. https:\/\/doi.org\/10.1056\/NEJMoa0806994","journal-title":"N Engl J Med"},{"issue":"1","key":"5716_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.psym.2018.05.011","volume":"60","author":"J Rivi\u00e8re","year":"2019","unstructured":"Rivi\u00e8re J, van der Mast RC, Vandenberghe J, Van Den Eede F (2019) Efficacy and tolerability of atypical antipsychotics in the treatment of delirium: a systematic review of the literature. Psychosomatics 60(1):18\u201326. https:\/\/doi.org\/10.1016\/j.psym.2018.05.011","journal-title":"Psychosomatics"},{"issue":"10","key":"5716_CR53","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350(10):1013\u20131022. https:\/\/doi.org\/10.1056\/NEJMra032426","journal-title":"N Engl J Med"},{"issue":"3","key":"5716_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1130-6343(09)71155-9","volume":"33","author":"A Rodr\u00edguez-Terol","year":"2009","unstructured":"Rodr\u00edguez-Terol A, Caraballo MO, Palma D, Santos-Ramos B, Molina T, Desongles T, Aguilar A (2009) Calidad estructural de las bases de datos de interacciones. Farm Hosp 33(3):134\u2013146. https:\/\/doi.org\/10.1016\/S1130-6343(09)71155-9","journal-title":"Farm Hosp"},{"key":"5716_CR55","doi-asserted-by":"publisher","unstructured":"Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA (2020) Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.8630","DOI":"10.1001\/jama.2020.8630"},{"issue":"3","key":"5716_CR56","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/cpt.250","volume":"99","author":"F Salvo","year":"2016","unstructured":"Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, Raschi E, Fourrier-R\u00e9glat A, Moore N, Sturkenboom M, Hazell On Behalf Of Investigators Of The Aritmo Consortium, L., & Investigators of the ARITMO Consortium (2016) Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther 99(3):306\u2013314. https:\/\/doi.org\/10.1002\/cpt.250","journal-title":"Clin Pharmacol Ther"},{"key":"5716_CR57","doi-asserted-by":"publisher","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6019","DOI":"10.1001\/jama.2020.6019"},{"key":"5716_CR58","doi-asserted-by":"publisher","unstructured":"Shukla AM, Archibald LK, Shukla AW, Mehta HJ, Cherabuddi K (2020) Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs Context 9. https:\/\/doi.org\/10.7573\/dic.2020-4-5","DOI":"10.7573\/dic.2020-4-5"},{"issue":"9","key":"5716_CR59","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"20","key":"5716_CR60","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.2174\/0929867043364351","volume":"11","author":"L Testai","year":"2004","unstructured":"Testai L, Bianucci AM, Massarelli I, Breschi MC, Martinotti E, Calderone V (2004) Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels. Curr Med Chem 11(20):2691\u20132706. https:\/\/doi.org\/10.2174\/0929867043364351","journal-title":"Curr Med Chem"},{"key":"5716_CR61","unstructured":"Truven Health Analytics. Micromedex\u00ae Solutions Drugs Interaction [electronic version] (2020) Retrieved from http:\/\/www.micromedexsolutions.com. Accessed 23 June 2020"},{"key":"5716_CR62","unstructured":"University of Liverpool. Liverpool COVID-19 Interactions (2020) Retrieved from https:\/\/www.covid19-druginteractions.org\/prescribing-resources. Accessed 23 June 2020"},{"issue":"6","key":"5716_CR63","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/gps.4037","volume":"29","author":"RM van der Linde","year":"2014","unstructured":"van der Linde RM, Dening T, Matthews FE, Brayne C (2014) Grouping of behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry 29(6):562\u2013568. https:\/\/doi.org\/10.1002\/gps.4037","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"5716_CR64","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MLR.0000000000000975","volume":"56","author":"EE Vasilevskis","year":"2018","unstructured":"Vasilevskis EE, Chandrasekhar R, Holtze CH, Graves J, Speroff T, Girard TD, Patel MB, Hughes CG, Cao A, Pandharipande PP, Ely EW (2018) The cost of ICU delirium and coma in the intensive care unit patient. Med Care 56(10):890\u2013897. https:\/\/doi.org\/10.1097\/MLR.0000000000000975","journal-title":"Med Care"},{"issue":"12","key":"5716_CR65","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","volume":"26","author":"WVR Vieweg","year":"2009","unstructured":"Vieweg WVR, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26(12):997\u20131012. https:\/\/doi.org\/10.2165\/11318880-000000000-00000","journal-title":"Drugs Aging"},{"issue":"6","key":"5716_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","volume":"63","author":"AI Vitry","year":"2007","unstructured":"Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63(6):709\u2013714. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02809.x","journal-title":"Br J Clin Pharmacol"},{"issue":"25","key":"5716_CR67","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehu176","volume":"35","author":"HJJ Wellens","year":"2014","unstructured":"Wellens HJJ, Schwartz PJ, Lindemans FW, Buxton AE, Goldberger JJ, Hohnloser SH, Huikuri HV, K\u00e4\u00e4b S, La Rovere MT, Malik M, Myerburg RJ, Simoons ML, Swedberg K, Tijssen J, Voors AA, Wilde AA (2014) Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J 35(25):1642\u20131651. https:\/\/doi.org\/10.1093\/eurheartj\/ehu176","journal-title":"Eur Heart J"},{"issue":"12","key":"5716_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/2045125318804499","volume":"8","author":"E Whiskey","year":"2018","unstructured":"Whiskey E, O\u2019Flynn D, Taylor D (2018) Clozapine, HIV and neutropenia: a case report. Ther Adv Psychopharmacol 8(12):365\u2013369. BASE. https:\/\/doi.org\/10.1177\/2045125318804499","journal-title":"Ther Adv Psychopharmacol"},{"issue":"8","key":"5716_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7(8):549\u2013558. https:\/\/doi.org\/10.1016\/S1473-3099(07)70187-1","journal-title":"Lancet Infect Dis"},{"key":"5716_CR70","unstructured":"Wolters Kluwer (2020) Wolters Kluwer. Lexicomp\u00ae Interactions Module [Internet]. Retrieved from https:\/\/www.wolterskluwercdi.com\/lexicomp-online\/. Accessed 23 June 2020"},{"key":"5716_CR71","unstructured":"Woosley RL, Heise CW, Gallo T, Woosley RD, and Romero KA, QTFactors List (n.d.-a) Retrieved from https:\/\/www.crediblemeds.org\/ndfa-list\/. Accessed 26 Sep 2020"},{"key":"5716_CR72","unstructured":"Woosley RL, Heise CW, Romero KA CredibleMeds \u00ae (2020) Retrieved from https:\/\/www.crediblemeds.org\/. Accessed 23 June 2020"},{"issue":"1","key":"5716_CR73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-020-05716-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T05:27:14Z","timestamp":1611379634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-020-05716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5716"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05716-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.04.20122416","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"31 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Plasencia-Garc\u00eda B.O. has received honoraria for consulting\/advisory boards from Otsuka Pharmaceuticals, Lundbeck, and Janssen Johnson & Johnson and lecture honoraria from Otsuka Pharmaceuticals, Lundbeck, Janssen Johnson & Johnson, Angelini, and Pfizer. Crespo-Facorro B. has received honoraria for consulting\/advisory boards from Otsuka Pharmaceuticals, Takeda, and Angelini and lecture honoraria from Janssen Johnson & Johnson, Lundbeck, Roche, and Otsuka Pharmaceutical. The other authors declare that they have no known conflicts of interest. No pharmaceutical industry or institutional sponsors participated in the study design, data collection, analysis, and interpretation of the results","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}